Irish sites manufacture approximately half of MSD’s top 20 products, saving and enhancing lives in over 60 countries around the world.
Some 220 short-term construction roles and 20 long-term production roles are to be created by the expansion of the MSD Ballydine site in Tipperary.
As part of the latest wave of investment in its facility in Ballydine Co. Tipperary, MSD (Merck Sharp & Dohme) is seeking to extend its Research & Development and Formulation building, with a view to being ready to support the pipeline of new medicines that the company is developing in the coming years.
“We’re very excited as a team to continue to attract investment from our company and are firmly focused on the future and the medicines of tomorrow”
Subject to planning permission being granted, the current building will be extended by a total of 6400sqmwith the addition of a new three-story extension which will contain the latest equipment and technology to support development and launch of pipeline medicines. MSD hopes to complete design and initial construction work in 2020 and start full construction in 2021, with a view to the new building being operational and commencing production in 2023.
“MSD Ballydine plays a pivotal role in our company’s global network, manufacturing commercial products and developing new medicines,” explained plant manager at MSD Ballydine Brian Killen.
MSD’s Ballydine site currently has a team of approximately 500 and the planned expansion of the R&D and Formulation building will lead to the addition of approximately 20 new staff in the areas of product development, operations and quality. In the short term, the construction project will also be supported by approximately 220 people, such as trade contractors and construction workers, peaking in 2021.
A chemical connection
MSD Ballydine is one of MSD’s five current sites in Ireland with sister sites located in Carlow, Cork and Dublin. MSD also recently announced the conclusion of an agreement to acquire an additional site in Dunboyne.
One of Ireland’s leading healthcare companies, MSD Ireland employs approximately 2,500 people across its manufacturing, human health and animal health businesses.
To date, MSD has invested approximately $3bn in its Irish operations and its annual turnover ranks MSD as one of Ireland’s top 20 companies.
Significantly, Irish sites manufacture approximately half of MSD’s top 20 products, saving and enhancing lives in over 60 countries around the world.
“Work relating to many of MSD’s key pipeline medicines is undertaken at our state-of-the-art research and commercialisation facility and we export to approximately 25 countries around the world for further processing,” said Killen.
“With this in mind we are continuously focused on the future and on how our site can be ready to support the development and launch of the next wave of important medicines.
“This has led to significant regular investment in the site over recent years and will ensure our facility continues to be invested in by our global company, in recognition of the role we play in realising the medicines of tomorrow.
“We’re very excited as a team to continue to attract investment from our company and are firmly focssed on the future and the medicines of tomorrow, with the aim that Ballydine continues to play an active and ongoing role in supporting this critical area. The additional expansion is a further endorsement of the highly-skilled team we have working here in Ballydine and the important work that they do,” Killen concluded.
Written by John Kennedy (firstname.lastname@example.org)
Published: 27 August, 2020